ArticleFamilial cancer2021

Complete response of hereditary leiomyomatosis and renal cell cancer (HLRCC)-associated renal cell carcinoma to nivolumab and ipilimumab combination immunotherapy by: a case report.

Yasuhiro Iribe et al.PubMed ↗Publisher ↗

No numbers read from the abstract.